



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

Important note: Unless otherwise indicated, medical policies will apply to all lines of business.

Medical necessity as defined by this policy does not ensure the benefit is covered. This medical policy does not replace existing federal or state rules and regulations for the applicable service or supply. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan documents. See the member plan specific benefit plan document for a complete description of plan benefits, exclusions, limitations, and conditions of coverage. In the event of a discrepancy, the plan document always supersedes the information in this policy.

SERVICE: Autism spectrum disorders (ASDs), includes diagnoses of Autistic Disorder, Asperger's Disorder, Pervasive Developmental Disorder, Pervasive Developmental Disorder-Not Otherwise Specified

PRIOR AUTHORIZATION: Not Applicable

POLICY: Please review the plan's EOC (Evidence of Coverage) or Summary Plan Description (SPD) for coverage details.

Some BSWHP benefit plans specifically exclude therapy for learning disabilities, developmental delays, autism, and mental retardation. In addition, some benefit plans specifically exclude behavioral training or services that are considered educational or training in nature. In benefit plans where these exclusions are present, services that are considered behavioral training, such as applied behavioral analysis are not covered. Please refer to the applicable benefit plan contract to determine terms, conditions and limitations of coverage.

Note: Unless otherwise indicated (see below), this policy will apply to all lines of business.

For Medicare plans, please refer to appropriate Medicare NCD (National Coverage Determination) or LCD (Local Coverage Determination). Medicare NCD or LCD specific InterQual criteria may be used when available. If there are no applicable NCD or LCD criteria, use the criteria set forth below.

For Medicaid plans, please confirm coverage as outlined in the [Texas Medicaid Provider Procedures Manual | TMHP](#) (TMPPM). If there are no applicable criteria to guide medical necessity decision making in the TMPPM, use the criteria set forth below.

BSWHP may consider certain procedures and services medically necessary for the **assessment of autism spectrum disorders (ASD)** when the member meets **ANY** of the criteria listed below:

1. Any loss of language or social skills for children under the age of 10 years that cannot be attributed to head trauma or other disease process; **OR**
2. No 2-word spontaneous (not just echolalic) phrases by 24 months; **OR**
3. No babbling by 12 months; **OR**
4. No gesturing (e.g., pointing, waving bye-bye) by 12 months; **OR**
5. No single words by 16 months



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

When the above criterion is met, **BSWHP may consider the following services** as medically necessary for the **assessment of suspected or known ASD**:

1. Medical evaluation including history and physical examination
2. Autism-specific developmental screening (e.g., Checklist for Autism in Toddlers [CHAT], Pervasive Developmental Disorder Screening Test-II, Autism Behavior Checklist [ABC], Childhood Autism Rating Scale [CARS])
3. Behavioral health evaluation including psychiatric examination
4. Evaluation by speech and language pathologist when deficits are present
5. Occupational and/or physical therapy evaluation when motor deficits, motor planning or sensory dysfunction are present
6. Audiological evaluation
7. Electroencephalogram (EEG) when there is suspicion of a seizure
8. Neuroimaging studies when the child is a candidate for specific surgical interventions such as epilepsy surgery
9. Lead screening
10. Quantitative plasma amino acid assays to detect phenylketonuria

For patients with an **established diagnosis** of autism spectrum disorder (ASD), **BSWHP may consider Intensive behavioral health treatment (e.g., behavior modification, applied behavior analytics, or other forms of psychotherapy)** as medically necessary for treatment when **ALL** of the following criteria are met:

1. Treatment is being provided by a licensed and certified behavioral health care professional, **in continuous presence, AND**
2. Meaningful and measurable improvement is expected from the therapy, **AND**
3. Prescribed in relation to autism spectrum disorder by the member's primary care physician or member's psychiatrist in the treatment plan recommended for the member, **AND**
4. A formal documented plan to include family training and education to assure identified interventions are carried out, has been submitted with the request

Note: Texas SB 1484 in 2013 permitted insurance companies to limit the cost of coverage for enrollees 10 years of age or older for applied behavior analysis to \$36,000 per year.

BSWHP may also cover assessment and treatment of comorbid behavioral health and/or medical diagnoses and associated symptoms and/or conditions under applicable medical and behavioral health benefit plans.

BSWHP does **NOT** cover neuropsychological testing for the assessment and/or treatment of ASD because such testing is rarely considered medically necessary.



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

BSWHP does **NOT** cover ANY of the following procedures or services for the assessment and/or treatment of ASD because they are considered experimental, investigational or unproven. (This list may not be all-inclusive):

1. Allergy testing (including, but not limited to, food allergy for gluten, casein, Candida and other molds)
2. Electronystagmography (in the absence of dizziness, vertigo, or balance disorder)
3. Erythrocyte glutathione peroxidase studies
4. Event-related potentials (i.e., evoked potential studies)
5. Hair analysis
6. Heavy metal testing
7. Homocysteine level testing
8. Immunologic or neurochemical abnormalities testing
9. Intestinal permeability studies
10. Magnetoencephalography
11. Micronutrient testing (e.g., vitamin level)
12. Mitochondrial disorders testing (e.g., lactate and pyruvate)
13. Neuroimaging studies such as: CT, MRI, MRS, PET, SPECT, and Functional MRI
14. Provocative chelation tests for mercury
15. Stool Analysis
16. Trace Metal Testing
17. Tympanometry (in the absence of hearing loss)
18. Urinary peptide testing
19. Vision Therapy

BSWHP does **NOT** cover ANY of the following procedures or services for the assessment and/or treatment of ASD because they are considered experimental, investigational or unproven. (This list may not be all-inclusive):

1. Acupuncture
2. Art therapy
3. Auditory integration therapy
4. Chelation therapy
5. Cognitive rehabilitation
6. Craniosacral therapy (e.g., chiropractic manipulation)
7. Dietary and nutritional interventions (e.g., elimination diets, vitamins)
8. EEG biofeedback/neurofeedback
9. Equestrian therapy (hippotherapy)
10. Facilitated communication
11. Floor time therapy
12. Holding therapy
13. Hyperbaric oxygen therapy
14. Immune globulin therapy



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

15. Immunologic or neurochemical abnormalities testing
16. Music therapy and rhythmic entrainment interventions
17. Nutritional, Mineral and Herbal Supplements (e.g., megavitamins, high dose pyridoxine, and magnesium, dimethylglycine and glutathione, calcium, germanium, selenium, tin, tungsten, vanadium, zinc, echinacea, berberis, etc.)
18. Recreational therapy
19. Secretin infusion
20. Sensory integration therapy
21. Sensory Integration Therapy (including, but not limited to, Berard Auditory integration training [AIT]; The Audio Tone Enhancer/Trainer; Digital Auditory Aerobics; Electronic Auditory Stimulation effect (EASE program); Kirby Auditory Modulation System (KAMS); SAMONAS Sound Therapy; Tomatis Sound Therapy The LiFTTM; The Listening Program)
22. Squeeze machine therapy

BSWHP does **NOT** cover general consumer electronic devices including (but not limited to); computers, smart phones, personal digital assistants (PDAs), tablet devices (e.g., iPads), electronic mail devices and pagers, for the assessment and/or treatment of ASD because they are not medical in nature.

BSWHP does **NOT** cover genetic screening for ASD in the general population because such screening is considered not medically necessary and of unproven benefit.

BACKGROUND:

Autism, Asperger's and Pervasive Developmental Disorder NOS ("not otherwise specified") comprise the Autism Spectrum Disorders (ASD). Today, about 1 in 68 children has been identified with an autism spectrum disorder (ASD) according to estimates from CDC's Autism and Developmental Disabilities Monitoring (ADDM) Network. Autism occurs in all racial, ethnic, and social groups and is almost five times more likely to occur in boys than girls. Autism impairs a person's ability to communicate and relate to others. It is also associated with rigid routines and repetitive behaviors, such as obsessively arranging objects or following very specific routines. Symptoms can range from very mild to severe.

Research has shown that a diagnosis of autism at age 2 can be reliable, valid, and stable. Parents may be the first to notice their child's unusual behaviors or their child's failure to reach appropriate developmental milestones. Some parents describe a child who seemed different from birth, while others describe a child who was developing normally and then lost skills.

There is no single treatment approach for all children with ASD, but highly structured educational/behavioral programs are central in most treatment plans. There are many program models, but the American Academy of Pediatrics has identified a number of common components that most successful treatment models share:



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

1. Entry into intervention as soon as an ASD diagnosis is seriously considered rather than deferring until a definitive diagnosis is made;
2. Active engagement of the child at least 25 hours per week, 12 months per year, in systematically planned, developmentally appropriate educational activities designed to address identified objectives;
3. Low child-to-teacher ratio to allow sufficient amounts of 1:1 and small group time;
4. Inclusion of a family component;
5. Promotion of opportunities for interaction with typically developing peers to the extent that these opportunities are available and helpful;
6. Ongoing measurement and documentation of the individual child's progress toward objectives, with adjustments in programming as needed;
7. Incorporation of a high degree of structure through elements such as predictable routine, visual activity schedules, and clear physical boundaries to minimize distractions;
8. Strategies to apply learned skills to new environments and situations (generalization) and to maintain functional use of these skills;
9. Use of assessment-based curricula that address: functional, spontaneous communication; social skills; adaptive skills that prepare the child for increased responsibility and independence; reduction of disruptive or maladaptive behavior; cognitive skills; and more.

There is no cure for Autism Spectrum Disorders. However appropriate intervention with scientifically validated approaches, used in conjunction with parents or guardians who rigidly follow prescribed treatment plans, can result in many individuals with Autism Spectrum Disorders living a highly functional, productive and full life.

MANDATES:

Texas: (TIC Section 1355.015 and 28 TAC Sections 21.4401—21.4404)

- At a minimum, an EOC must provide coverage to an enrollee diagnosed with autism spectrum disorder from the date of diagnosis until the enrollee completes nine years of age.
- An EOC must provide coverage for all generally recognized services prescribed in relation to autism spectrum disorder by the enrollee's primary care physician in the treatment plan recommended by that physician. This coverage may be subject to annual deductibles, copayments, and coinsurance. "Generally recognized services" includes applied behavior analysis; speech, occupational and physical therapy; medications or nutritional supplements; and other treatments.

Texas SB 1484, July 17, 2013, amends current law by removing the age restriction for children with the diagnosis of autism by the age of 10 years. *Senate Bill 1484* amends provisions of the Insurance Code relating to mandatory health benefit plan coverage for enrollees diagnosed with autism spectrum disorder. Previous law required a health benefit plan to provide such coverage only until the enrollee completed nine years of age. The bill requires a health benefit plan to provide coverage to any enrollee



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

whose diagnosis was in place prior to the enrollee's 10th birthday, regardless of the enrollee's age. However, the bill establishes that a health benefit plan is not required to provide coverage for an enrollee 10 years of age or older for applied behavior analysis in an amount that exceeds \$36,000 per year. The bill specifies that a qualified health plan, as defined by federal law, is not required to provide a benefit to an enrollee diagnosed with autism spectrum disorder that exceeds the specified essential health benefits required under the federal Patient Protection and Affordable Care Act to the extent that the state would be required to make a payment to defray the cost of the additional benefit.

CODES:

Important note: Due to the wide range of applicable diagnosis codes and potential changes to codes, an inclusive list may not be presented, but the following codes may apply. Inclusion of a code in this section does not guarantee that it will be reimbursed, and patient must meet the criteria set forth in the policy language.

CPT Codes	Covered when Medically Necessary for Treatments of ASD 0362T, 0373T - Adaptive behavior treatment by protocol 97151, 97152 97153, 97154, 97155, 97156, 97157, 97158 – Adaptive behavior treatment interventions
CPT Codes NOT covered Educational in nature and NOT covered unless specified by state mandate or plan contract:	96116 - Neurobehavioral status exam (clinical assessment of thinking, reasoning and judgment, eg, acquired knowledge, attention, language, memory, planning and problem solving, and visual spatial abilities), per hour of the psychologist's or physician's time, both face-to-face time with the patient and time interpreting test results and preparing the report 96118 - Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), per hour of the psychologist's or physician's time, both face-to-face time with the patient and time interpreting test results and preparing the report 96119 - Neuropsychological testing (eg, Halstead-Reitan Neuropsychological Battery, Wechsler Memory Scales and Wisconsin Card Sorting Test), with qualified health care professional interpretation and report, administered by technician, per hour of technician time, face-to-face 96120 - Neuropsychological testing (eg, Wisconsin Card Sorting Test), administered by a computer, with qualified health care professional interpretation and report
CPT Codes NOT covered Experimental, Investigational, Unproven NOT Covered when used for the assessment of	82705 - Fat or lipids, feces; qualitative 83018 - Heavy metal (eg, arsenic, barium, beryllium, bismuth, antimony, mercury);quantitative, each 83615 - Lactate dehydrogenase (LD) (LDH) 86001 - Allergen specific IgG quantitative or semiquantitative, each allergen 86003 - Allergen specific IgE; quantitative or semiquantitative, each allergen 86005 - Allergen specific IgE; qualitative, multiallergen screen (dipstick, paddle, or disk) 86485 - Skin test; candida 92585 - Auditory evoked potentials for evoked response audiometry and/or testing of the



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

<p>autism spectrum disorders</p>	<p>central nervous system; comprehensive</p> <p>92586 - Auditory evoked potentials for evoked response audiometry and/or testing of the central nervous system; limited</p> <p>95004 - Percutaneous tests (scratch, puncture, prick) with allergenic extracts, immediate type reaction, including test interpretation and report by physician, specify number of tests</p> <p>95010 - Percutaneous tests (scratch, puncture, prick), sequential and incremental, with drugs, biologicals or venoms, immediate type reaction, including test interpretation and report by physician, specify number of tests</p> <p>95075 - Ingestion challenge test (sequential and incremental ingestion of test items, eg, food, drug or other substance such as metabisulfite)</p> <p>95930 - Visual evoked potential (VEP) testing central nervous system, checkerboard or flash</p> <p>95965 - Magnetoencephalography (MEG), recording and analysis; for spontaneous brain magnetic activity (eg, epileptic cerebral cortex localization)</p> <p>95966 - Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, single modality (eg, sensory, motor, language, or visual cortex localization)</p> <p>95967 - Magnetoencephalography (MEG), recording and analysis; for evoked magnetic fields, each additional modality (eg, sensory, motor, language, or visual cortex localization) (List separately in addition to code for primary procedure)</p>
<p>CPT Codes NOT covered</p> <p>Experimental, Investigational, Unproven NOT Covered when used for the treatment of autism spectrum disorders</p>	<p>90281 - Immune globulin (Ig), human, for intramuscular use</p> <p>90283 - Immune globulin (IgIV), human, for intravenous use</p> <p>90284 - Immune globulin (SCIg), human, for use in subcutaneous infusions, 100 mg, each</p> <p>90875 - Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); approximately 20-30 minutes</p> <p>90876 - Individual psychophysiological therapy incorporating biofeedback training by any modality (face-to-face with the patient), with psychotherapy (eg, insight oriented, behavior modifying or supportive psychotherapy); approximately 45-50 minutes</p> <p>90901 - Biofeedback training by any modality</p> <p>92065 - Orthoptic and/or pleoptic training, with continuing medical direction and evaluation</p> <p>97532 - Development of cognitive skills to improve attention, memory, problem solving (includes compensatory training), direct (one-on-one) patient contact by the provider, each 15 minutes</p> <p>97533 - Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one), patient contact by the provider, each 15 minutes</p> <p>97810 - Acupuncture, 1 or more needles; without electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient</p> <p>97811 - Acupuncture, 1 or more needles; without electrical stimulation, each additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)</p> <p>97813 - Acupuncture, 1 or more needles; with electrical stimulation, initial 15 minutes of personal one-on-one contact with the patient</p> <p>97814 - Acupuncture, 1 or more needles; with electrical stimulation, each</p>



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

	<p>additional 15 minutes of personal one-on-one contact with the patient, with re-insertion of needle(s) (List separately in addition to code for primary procedure)</p> <p>99183 - Physician attendance and supervision of hyperbaric oxygen therapy, per session</p>
<p>HCPCS Codes NOT covered</p> <p><i>Experimental, Investigational, Unproven NOT Covered when used for the treatment of autism spectrum disorders</i></p>	<p>A4575 - Topical hyperbaric oxygen chamber, disposable</p> <p>C1300 - Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval</p> <p>E1902 - Communication board, non-electronic augmentative or alternative communication device</p> <p>G0176 - Activity therapy, such as music, dance, art or play therapies not for recreation, related to the care and treatment of patient's disabling mental health problems, per session (45 minutes or more)</p> <p>J1459 - Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g. liquid), 500 MG</p> <p>J1557 - Injection, immune globulin, (Gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg (code effective 01/01/2012)</p> <p>J1559 - Injection, immune globulin (Hizentra), 100 mg</p> <p>J1561 - Injection, immune globulin, (Gamunex), intravenous, nonlyophilized (e.g., liquid), 500 mg</p> <p>J1562 - Injection, immune globulin (Vivaglobin), 100 mg</p> <p>J1566 - Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg</p> <p>J1568 - Injection, immune globulin, (Octagam), intravenous, nonlyophilized (e.g., liquid), 500 mg</p> <p>J1569 - Injection, immune globulin, (Gammagard liquid), intravenous, nonlyophilized, (e.g., liquid), 500 mg</p> <p>J1572 - Injection, immune globulin, (Flebogamma), intravenous, nonlyophilized (e.g., liquid), 500 mg</p> <p>J1599 - Injection, immune globulin, intravenous, non-lyophilized (e.g. liquid), not otherwise specified</p> <p>J2850 - Injection, secretin, synthetic, human, 1 mcg</p> <p>S8940 - Equestrian/hippotherapy, per session</p> <p>S9355 - Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem</p>
ICD10 Codes	F84.0F84.9 - Autism spectrum disorder

POLICY HISTORY:

Status	Date	Action
New	08/02/2012	New policy
Reviewed	02/28/2013	Reviewed. Minor revisions made.
Reviewed	02/20/2014	Reviewed and updated with mandate. ICD10 codes added.



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

Reviewed	03/26/2015	Updated mandate language
Reviewed	03/17/2016	Reviewed
Reviewed	09/01/2016	Clarified language when lacking of medical necessity.
Reviewed	03/07/2017	Created separate policy for treatment – see 232
Reviewed	01/30/2018	No changes
Reviewed	07/30/2020	Language added to include First Care
Reviewed	07/22/2021	Minor update: delete extraneous comment in Overview
Reviewed	09/22/2022	No changes
Reviewed	09/22/2023	Formatting changes, added hyperlinks to NCD and TMPPM, beginning and ending note sections updated to align with CMS requirements and business entity changes
Reviewed	07/24/2024	Updated references

REFERENCES:

The following scientific references were utilized in the formulation of this medical policy. BSWHP will continue to review clinical evidence surrounding acupuncture with and without electrical stimulation and may modify this policy at a later date based upon the evolution of the published clinical evidence. Should additional scientific studies become available, and they are not included in the list, please forward the reference(s) to BSWHP so the information can be reviewed by the Medical Coverage Policy Committee (MCPC) and the Quality Improvement Committee (QIC) to determine if a modification of the policy is in order

1. Abdul-Rahman OA, Hudgins L. The diagnostic utility of a genetics evaluation in children with pervasive developmental disorders. *Genet Med*. 2006 Jan;8(1):50-4.
2. Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). Indications for Hyperbaric Oxygen Therapy: Update. 2008. Accessed March 2012. Available at URL address: <http://www.aetmis.gouv.qc.ca/site/250.1093.0.0.1.0.phtml>
3. Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS). The role of hyperbaric oxygen therapy in the management of autism. Nov 2007. Accessed March 2012. Available at URL address: <http://www.aetmis.gouv.qc.ca/site/250.1054.0.0.1.0.phtml>
4. American Academy of Child & Adolescent Psychiatry (AACAP). Policy statement. Secretin in the Treatment of Autism. Revised and approved by Council June 15, 2002. Accessed March 2012. Available at URL address: <http://www.aacap.org/page.ww?section=Policy+Statements&name=Secretin+in+the+Treatment+of+Autism>
5. American Academy of Child & Adolescent Psychiatry (AACAP). Policy statement: facilitated communication. Approved by Council, October 20. 1993. Reviewed June, 2008. Accessed March 2012. Available at URL address: <http://www.aacap.org/page.ww?section=Policy+Statements&name=Facilitated+Communication>
6. American Academy of Pediatrics (AAP). Committee on Children with Disabilities. Auditory integration training and facilitated communications for autism. *Pediatrics*. 1998 Aug;102(2 Pt 1):431-3. A statement of reaffirmation for this policy was published on February 1, 2010. Accessed March 2012. Available at URL address: <http://aappolicy.aappublications.org/cgi/content/full/pediatrics;102/2/431>
7. American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 469: Carrier screening for fragile X syndrome. *Obstet Gynecol*. 2010 Oct;116(4):1008-10.

MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, D.C. American Psychiatric Association APA, 2000
9. American Psychological Association (APA). Resolution on Facilitated Communication. Adopted in Council, August 14, 1994. Accessed March 2012. Available at URL address: <http://www.apa.org/divisions/div33/fcpolicy.html>
10. American Speech-Language-Hearing Association (ASHA). Augmentative and Alternative Communication (AAC). Accessed March 2012. Available at URL address: <http://www.asha.org/public/speech/disorders/AAC.htm> Page 25 of 36
11. American Speech-Language-Hearing Association (ASHA). Guidelines for Speech-Language Pathologists in Diagnosis, Assessment, and Treatment of Autism Spectrum Disorders Across the Life Span [Guidelines]. 2006a. Accessed March 2012. Available at URL address: <http://www.asha.org/docs/pdf/GL2006-00049.pdf>
12. American Speech-Language-Hearing Association (ASHA). Principles for Speech-Language Pathologists in Diagnosis, Assessment, and Treatment of Autism Spectrum Disorders Across the Life Span [Technical Report]. 2006b. Accessed March 2012. Available at URL address: <http://www.asha.org/docs/html/TR2006-00143.html>
13. Archer HL, Whatley SD, Evans JC, Ravine D, Huppke P, Kerr A, et al. Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet. 2006 May;43(5):451-6. Epub 2005 Sep 23.
14. Association for Science in Autism Treatment (ASAT). Autism Treatments: Descriptions and Research Summaries. Accessed March 2012. Available at URL address: <http://www.asatonline.org/intervention/autismtreatments.htm>
15. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2000 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, six sites, United States, 2000. MMWR Surveill Summ. 2007 Feb 9;56(1):1-11.
16. Ball CM. Music therapy for children with autistic spectrum disorder. In Bazian Ltd (Ed) STEER: Succinct and Timely Evaluated Evidence Reviews 2004; 4(1). Bazian Ltd and Wessex Institute for Health Research & Development, University of Southampton. Accessed March 2012. Available at URL address: [http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2004\(1\).pdf](http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2004(1).pdf)
17. Barbaresi WJ, Katusic SK, Voigt RG. Autism: a review of the state of the science for pediatric primary health care clinicians. Arch Pediatr Adolesc Med. 2006 Nov;160(11):1167-75.
18. Battaglia A, Bonaglia MC. The yield of subtelomeric FISH analysis in the evaluation of autistic spectrum disorders. Am J Med Genet C Semin Med Genet. 2006 Feb 15;142(1):8-12.
19. Ben-Itzhak E, Zachor DA. The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil. 2007 May-Jun;28(3):287-303.
20. Ben-Itzhak E, Zachor DA. The effects of intellectual functioning and autism severity on outcome of early behavioral intervention for children with autism. Res Dev Disabil. 2007 May-Jun;28(3):287-303.
21. Blue Cross Blue Shield Association. Special Report: Special Report: Early Intensive Behavioral Intervention Based on Applied Behavior Analysis among Children with Autism Spectrum Disorders. Assessment Program: Volume 23, No. 9. February 2009. Accessed: October 28, 2011. Available at URL address: <http://www.bcbs.com/blueresources/tec/press/special-report-early.html>
22. BlueCross BlueShield Association (BCBSA). Technology Evaluation Center (TEC). Special Report: aCGH for the Genetic Evaluation of Patients with Developmental Delay/Mental Retardation or Autism Spectrum Disorder TEC Assessment Program. Vol 25. No. 10. Chicago, IL. BCBSA. 2009 Apr. Accessed March 2012. Available at URL address: <http://www.bcbs.com/blueresources/tec/press/array-comparative-genomic-hybridization.html>
23. BlueCross BlueShield Association (BCBSA). Technology Evaluation Center (TEC). Special Report: Special Report: Early Intensive Behavioral Intervention Based on Applied Behavior Analysis among Children with Autism Spectrum Disorders. Assessment Program: Volume 23, No. 9. February 2009. Accessed: October 25, 2011. Available at URL address: <http://www.bcbs.com/blueresources/tec/press/special-report-early.html>
24. Broadstock, M and Doughty, C. The effectiveness of pharmacological therapies for young people and adults with Autism Spectrum Disorder (ASD). NZHTA Report 2003; 6(1). Accessed March 2012. Available at URL address: <http://nzhta.chmeds.ac.nz/index.htm#review>
25. Brown KA, Patel DR. Complementary and alternative medicine in developmental disabilities. Indian J Pediatr. 2005

MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

Nov;72(11):949-52.

26. Callahan K, Shukla-Mehta S, Magee S, Wie M. ABA versus TEACCH: the case for defining and validating comprehensive treatment models in autism. *J Autism Dev Disord*. 2010 Jan;40(1):74-88.
27. Campbell JM. Efficacy of behavioral interventions for reducing problem behavior in persons with autism: a quantitative synthesis of single-subject research. *Res Dev Disabil*. 2003 Mar-Apr;24(2):120-38.
28. Canadian Paediatric Society. Early intervention for children with autism. *Paediatr Child Health* Vol 9 No 4 April 2004. Accessed March 2012. Available at URL address: <http://www.cps.ca/english/statements/PP/pp04-02.pdf>
29. Carayol J, Schellenberg GD, Tores F, Hager J, Ziegler A, Dawson G. Assessing the impact of a combined analysis of four common low-risk genetic variants on autism risk. *Mol Autism*. 2010 Feb 22;1(1):4.
30. Case-Smith J, Arbesman M. Evidence-based review of interventions for autism used in or of relevance to occupational therapy. *Am J Occup Ther*. 2008 Jul-Aug;62(4):416-29.
31. Case-Smith J, Bryan T. The effects of occupational therapy with sensory integration emphasis on preschool-age children with autism. *Am J Occup Ther*. 1999 Sep-Oct;53(5):489-97.
32. Centers for Disease Control and Prevention (CDC); Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators. Prevalence of autism spectrum disorders--autism and developmental disabilities monitoring network, 14 sites, United States, 2008. *MMWR Surveill Summ*. 2012 Mar 30;61(SS03):1-19.
33. Centers for Disease Control and Prevention (CDC); CADDRE: Centers for Autism and Developmental Disabilities Research and Epidemiology. 2006. Accessed March 2012. Available at URL address: <http://www.cdc.gov/ncbddd/autism/caddre.htm>
34. Charlop-Christy MH, Carpenter M, Le L, LeBlanc LA, Kellet K. Using the picture exchange communication system (PECS) with children with autism: assessment of PECS acquisition, speech, social-communicative behavior, and problem behavior. *J Appl Behav Anal*. 2002 Fall;35(3):213-31.
35. Cheuk DK, Wong V, Chen WX. Acupuncture for autism spectrum disorders (ASD). *Cochrane Database Syst Rev*. 2011 Sep 7;9:CD007849.
36. Christison GW, Ivany K. Elimination diets in autism spectrum disorders: any wheat amidst the chaff? *J Dev Behav Pediatr*. 2006 Apr;27(2 Suppl):S162-71.
37. Christodoulou J. MECP2-Related disorders. *Gene Reviews*. Funded by the NIH. Developed at the University of Washington, Seattle. Initial posting: 3 October 2001. Last update: April 2, 2009. Accessed March 2012. Available at URL address: <http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=rett>
38. Coben R, Linden M, Myers TE. Neurofeedback for autistic spectrum disorder: a review of the literature. *Appl Psychophysiol Biofeedback*. 2010 Mar;35(1):83-105.
39. Coben R, Myers TE. The relative efficacy of connectivity guided and symptom based EEG biofeedback for autistic disorders. *Appl Psychophysiol Biofeedback*. 2010 Mar;35(1):13-23.
40. Cohen H, Amerine-Dickens M, Smith T. Early intensive behavioral treatment: replication of the UCLA model in a community setting. *J Dev Behav Pediatr*. 2006 Apr;27(2 Suppl):S145-55.
41. Coplan J, Souders MC, Mulberg AE, Belchic JK, Wray J, Jawad AF, et al. Children with autistic spectrum disorders. II: parents are unable to distinguish secretin from placebo under double-blind conditions. *Arch Dis Child*. 2003 Aug;88(8):737-9.
42. Costello E. Complementary and alternative therapies: considerations for families after international adoption. *Pediatr Clin North Am*. 2005 Oct;52(5):1463-78, ix.
43. Council on Children With Disabilities; Section on Developmental Behavioral Pediatrics; Bright Futures Steering Committee; Medical Home Initiatives for Children With Special Needs Project Advisory Committee. Identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. *Pediatrics*. 2006 Jul;118(1):405-20.
44. Currenti SA. Understanding and determining the etiology of autism. *Cell Mol Neurobiol*. 2010 Mar;30(2):161-71. Epub 2009 Sep 23.
45. Dawson G, Rogers S, Munson J, Smith M, Winter J, Greenson J, et al. Randomized, controlled trial of an intervention for

MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

- toddlers with autism: the Early Start Denver Model. *Pediatrics*. 2010 Jan;125(1):e17-23.
46. Dawson G, Watling R. Interventions to facilitate auditory, visual, and motor integration in autism: a review of the evidence. *J Autism Dev Disord*. 2000 Oct;30(5):415-21.
47. Desch LW, Gaebler-Spira D; Council on Children With Disabilities. Prescribing assistive-technology systems: focus on children with impaired communication. *Pediatrics*. 2008 Jun;121(6):1271-80.
48. Desoto MC, Hitlan RT. Sorting out the spinning of autism: heavy metals and the question of incidence. *Acta Neurobiol Exp (Wars)*. 2010;70(2):165-76.
49. Diggle T, McConachie HR, Randle VR. Parent-mediated early intervention for young children with autism spectrum disorder. *Cochrane Database Syst Rev*. 2003;(1):CD003496.
50. Doughty C. What is the evidence for the effectiveness of behavioural and skill-based early intervention in young children with Autism Spectrum Disorder (ASD)? New Zealand Health Technology Assessment (NZHTA) Tech Brief Series 2004;3(1). Accessed March 2012. Available at URL address: <http://nzhta.chmeds.ac.nz/#tech>
51. Doughty C. What is the evidence for the effectiveness of behavioural and skill-based early intervention in young children with Autism Spectrum Disorder (ASD)? New Zealand Health Technology Assessment (NZHTA) Tech Brief Series 2004;3(1). Accessed March 2012. Available at URL address: <http://nzhta.chmeds.ac.nz/#tech>
52. Dua V. Standards and Guidelines for the Assessment and Diagnosis of Young Children with Autism Spectrum Disorder in British Columbia. An Evidence-Based Report prepared for The British Columbia Ministry of Health Planning. March 2003. Accessed March 2012. Available at URL address: <http://www.health.gov.bc.ca/library/publications/#autism>
53. ECRI Institute. Comprehensive Educational and Behavioral Interventions for Autism Spectrum Disorders). Plymouth Meeting (PA): ECRI Institute Health Technology Assessment Information Service; 2011 October. (Evidence Report; no. 167). Available at URL address: <http://www.ecri.org>.
54. Eikeseth S, Smith T, Jahr E, Eldevik S. Intensive behavioral treatment at school for 4- to 7-year-old children with autism. A 1-year comparison controlled study. *Behav Modif*. 2002 Jan;26(1):49-68.
55. Eikeseth S, Smith T, Jahr E, Eldevik S. Outcome for children with autism who began intensive behavioral treatment between ages 4 and 7: a comparison controlled study. *Behav Modif*. 2007 May;31(3):264-78.
56. Eldevik S, Eikeseth S, Jahr E, Smith T. Effects of low-intensity behavioral treatment for children with autism and mental retardation. *J Autism Dev Disord*. 2006 Feb;36(2):211-24.
57. Eldevik S, Eikeseth S, Jahr E, Smith T. Effects of low-intensity behavioral treatment for children with autism and mental retardation. *J Autism Dev Disord*. 2006 Feb;36(2):211-24.
58. Sandbank M, Bottema-Beutel K, Crowley S, Cassidy M, Dunham K, Feldman JI, Crank J, Albarran SA, Raj S, Mahbub P, Woynaroski TG. Project AIM: Autism intervention meta-analysis for studies of young children. *Psychol Bull*. 2020 Jan;146(1):1-29. doi: 10.1037/bul0000215. Epub 2019 Nov 25. PMID: 31763860; PMCID: PMC8783568.
59. Fabiano GA, Pelham WE Jr, Coles EK, Gnagy EM, Chronis-Tuscano A, O'Connor BC. A meta-analysis of behavioral treatments for attention-deficit/hyperactivity disorder. *Clin Psychol Rev*. 2009 Mar;29(2):129-40.
60. Filipek PA, Accardo PJ, Ashwal S, Baranek GT, Cook EH Jr, Dawson G, et al. Practice parameter: screening and diagnosis of autism: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Child Neurology Society. *Neurology*. 2000 Aug 22;55(4):468-79. (The guideline was reaffirmed by the developer on October 18, 2003, July 28, 2006, and July 10, 2010.)
61. Filipek PA, Steinberg-Epstein R, Book TM. Intervention for autistic spectrum disorders. *NeuroRx*. 2006 Apr;3(2):207-16.
62. Findling RL. Pharmacologic treatment of behavioral symptoms in autism and pervasive developmental disorders. *J Clin Psychiatry*. 2005;66 Suppl 10:26-31.
63. Freitag CM. The genetics of autistic disorders and its clinical relevance: a review of the literature. *Mol Psychiatry*. 2007 Jan;12(1):2-22.
64. Ganz JB, Earles-Vollrath TL, Heath AK, Parker RI, Rispoli MJ, Duran JB. A Meta-Analysis of Single Case Research Studies on Aided Augmentative and Alternative Communication Systems with Individuals with Autism Spectrum Disorders. *J Autism Dev Disord*. 2011 Mar 5. [Epub ahead of print]
65. Gold C, Wigram T, Elefant C. Music therapy for autistic spectrum disorder. *Cochrane Database Syst Rev*. 2006 Apr

MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number:	206
Effective Date:	08/01/2024
Last Review:	07/24/2024
Next Review:	07/24/2025

- 19;(2):CD004381.
66. Gordon K, Pasco G, McElduff F, Wade A, Howlin P, Charman T. A communication-based intervention for nonverbal children with autism: what changes? Who benefits? *J Consult Clin Psychol*. 2011 Aug;79(4):447-57.
 67. Granpeesheh D, Tarbox J, Dixon DR. Applied behavior analytic interventions for children with autism: a description and review of treatment research. *Ann Clin Psychiatry*. 2009 Jul-Sep;21(3):162-73.
 68. Green J, Charman T, McConachie H, Aldred C, Slonims V, Howlin P, et al.; PACT Consortium. Parent-mediated communication-focused treatment in children with autism (PACT): a randomized controlled trial. *Lancet*. 2010 Jun 19;375(9732):2152-60.
 69. Gropman AL, Batshaw ML. Epigenetics, copy number variation, and other molecular mechanisms underlying neurodevelopmental disabilities: new insights and diagnostic approaches. *J Dev Behav Pediatr*. 2010 Sep;31(7):582-91.
 70. Gutstein SE, Burgess AF, Montfort K. Evaluation of the relationship development intervention program. *Autism*. 2007 Sep;11(5):397-411.
 71. Gutstein SE. Empowering families through Relationship Development Intervention: an important part of the biopsychosocial management of autism spectrum disorders. *Ann Clin Psychiatry*. 2009 Jul-Sep;21(3):174-82.
 72. Happe F, Ronald A, Plomin R. Time to give up on a single explanation for autism. *Nat Neurosci*. 2006 Oct;9(10):1218-20.
 73. Harrington JW, Rosen L, Garnecho A, Patrick PA. Parental perceptions and use of complementary and alternative medicine practices for children with autistic spectrum disorders in private practice. *J Dev Behav Pediatr*. 2006 Apr;27(2 Suppl):S156-61.
 74. Hayward D, Eikeseth S, Gale C, Morgan S. Assessing progress during treatment for young children with autism receiving intensive behavioural interventions. *Autism*. 2009 Nov;13(6):613-33.
 75. Holtmann M, Steiner S, Hohmann S, Poustka L, Banaschewski T, Bölte S. Neurofeedback in autism spectrum disorders. *Dev Med Child Neurol*. 2011 Nov;53(11):986-93. doi: 10.1111/j.1469-8749.2011.04043.x. Epub 2011 Jul 14.
 76. Howard JS, Sparkman CR, Cohen HG, Green G, Stanislaw H. A comparison of intensive behavior analytic and eclectic treatments for young children with autism. *Res Dev Disabil*. 2005 Jul-Aug;26(4):359-83.
 77. Howlin P, Magiati I, Charman T. Systematic review of early intensive behavioral interventions for children with autism. *Am J Intellect Dev Disabil*. 2009 Jan;114(1):23-41.
 78. Jacquemont ML, Sanlaville D, Redon R, Raoul O, Cormier-Daire V, Lyonnet S, et al. Array-based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders. *J Med Genet*. 2006 Nov;43(11):843-9.
 79. Jepson B, Granpeesheh D, Tarbox J, Olive ML, Stott C, Braud S, et al. Controlled evaluation of the effects of hyperbaric oxygen therapy on the behavior of 16 children with autism spectrum disorders. *J Autism Dev Disord*. 2011 May;41(5):575-88.
 80. Jesner OS, Aref-Adib M, Coren E. Risperidone for autism spectrum disorder. *Cochrane Database Syst Rev*. 2007 Jan 24;(1):CD005040.
 81. Johnson CP, Myers SM; American Academy of Pediatrics Council on Children with Disabilities. Identification and evaluation of children with autism spectrum disorders. *Pediatrics*. 2007 Nov;120(5):1183-215. Epub 2007 Oct 29.
 82. Kasari C, Lawton K. New directions in behavioral treatment of autism spectrum disorders. *Curr Opin Neurol*. 2010 Apr;23(2):137-43.
 83. Kim J, Wigram T, Gold C. Emotional, motivational and interpersonal responsiveness of children with autism in improvisational music therapy. *Autism*. 2009 Jul;13(4):389-409.
 84. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am*. 2006 Jan;15(1):161-75.
 85. Krishnaswami S, McPheeters ML, Veenstra-Vanderweele J. A systematic review of secretin for children with autism spectrum disorders. *Pediatrics*. 2011 May;127(5):e1322-5. Epub 2011 Apr 4.
 86. Levy SE, Hyman SL. Complementary and alternative medicine treatments for children with autism spectrum disorders. *Child Adolesc Psychiatr Clin N Am*. 2008 Oct;17(4):803-20, ix.

MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

87. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. *Ment Retard Dev Disabil Res Rev*. 2005;11(2):131-42.
88. Levy SE, Souders MC, Wray J, Jawad AF, Gallagher PR, Coplan J, et al. Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin. *Arch Dis Child*. 2003 Aug;88(8):731-6.
89. Lintas C, Persico AM. Autistic phenotypes and genetic testing: state-of-the-art for the clinical geneticist. *J Med Genet*. 2009 Jan;46(1):1-8.
90. Ludwig S, Harstall C. Intensive intervention programs for children with autism. Alberta Heritage Foundation for Medical Research, 2001 Feb. Accessed March 2012. Available at URL address: http://www.ihe.ca/documents/HTA8_WEB_FINAL.pdf
91. Magiati I, Charman T, Howlin P. A two-year prospective follow-up study of community-based early intensive behavioural intervention and specialist nursery provision for children with autism spectrum disorders. *J Child Psychol Psychiatry*. 2007 Aug;48(8):803-12.
92. Makrygianni MK, Reed P. A meta-analytic review of the effectiveness of behavioural early intervention programs for children with autism spectrum disorders. *Res Autism Spectr Disord*. 2010;4:577-593.
93. McConkie-Rosell A, Finucane B, Cronister A, Abrams L, Bennett RL, Pettersen BJ. Genetic counseling for fragile X syndrome: updated recommendations of the National Society of Genetic Counselors. *J Genet Counsel* 2005 Aug;14(4):249-70.
94. McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al.; Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. *N Engl J Med*. 2002 Aug 1;347(5):314-21.
95. McEachin JJ, Smith T, Lovaas OI. Long-term outcome for children with autism who received early intensive behavioral treatment. *Am J Ment Retard*. 1993 Jan;97(4):359-72; discussion 373-91.
96. McMahon WM, Baty BJ, Botkin J. Genetic counseling and ethical issues for autism. *Am J Med Genet C Semin Med Genet*. 2006 Feb 15;142(1):52-7.
97. McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J. A systematic review of medical treatments for children with autism spectrum disorders. *Pediatrics*. 2011 May;127(5):e1312-21. Epub 2011 Apr 4.
98. Michaud LJ; Committee on Children With Disabilities. Prescribing therapy services for children with motor disabilities. *Pediatrics* [serial online]. 2004 Jun;113(6):1836-8. American Academy of Pediatrics (AAP) Policy. (Policy reaffirmed September 1, 2007; July 1, 2011). Accessed March 2012. Available at URL address: <http://aappolicy.aappublications.org/cgi/content/full/pediatrics;113/6/1836>
99. Miles JH, Mccathren RB, Stichter J, Shinawi M. Autism Spectrum Disorders. Gene Reviews. Funded by the NIH. Developed at the University of Washington, Seattle. Initial posting: August 27, 2003; Last Update: April 13, 2010. Accessed March 2012. Available at URL address: <http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=autism-overview>
100. Millar DC, Light JC, Schlosser RW. The impact of augmentative and alternative communication intervention on the speech production of individuals with developmental disabilities: a research review. *J Speech Lang Hear Res*. 2006 Apr;49(2):248-64.
101. Millward C, Ferriter M, Calver S, Connell-Jones G. Gluten- and casein-free diets for autistic spectrum disorder. *Cochrane Database Syst Rev*. 2008 Apr 16;(2):CD003498.
102. Muhle R, Trentacoste SV, Rapin I. The genetics of autism. *Pediatrics*. 2004 May;113(5):e472-86.
103. Myers SM, Johnson CP; American Academy of Pediatrics Council on Children with Disabilities. Management of children with autism spectrum disorders. *Pediatrics*. 2007 Nov;120(5):1162-82. (Reaffirmed December 1, 2010)
104. National Institute for Health and Clinical Excellence (NICE) (United Kingdom). Autism: recognition, referral and diagnosis of children and young people on the autism spectrum. (NICE clinical guideline 128). 2011. Accessed March 2012. Available at URL address: <http://guidance.nice.org.uk/CG128>
105. National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH).



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

Autism and Genes. NIH Pub. No. 05-5590. May 2005 (b). Accessed March 2012. Available at URL address:

http://www.nichd.nih.gov/publications/pubs/upload/autism_genes_2005.pdf

106. National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH). Autism Overview: What We Know. NIH Pub. No. 05-5592. May 2005 (a). Accessed March 2012. Available at URL address: http://www.nichd.nih.gov/publications/pubs/upload/autism_overview_2005.pdf#page=5
107. National Institute of Mental Health (NIMH). Autism Spectrum Disorders (Pervasive Developmental Disorders). NIH Publication No. NIH-04-5511, National Institutes of Health (NIH), U.S. Department of Health and Human Services, Bethesda, MD. 2004. Last reviewed: December 2010. Accessed March 2012. Available at URL address: <http://www.nimh.nih.gov/publicat/autism.cfm>
108. National Institute of Neurological Disorders and Stroke (NINDS). National Institutes of Health. Asperger Syndrome Information Page. Last updated June 15, 2011. Accessed March 2012. Available at URL address: <http://www.ninds.nih.gov/disorders/asperger/asperger.htm>
109. National Institute of Neurological Disorders and Stroke (NINDS). National Institutes of Health. Autism Fact Sheet. Last updated September 30, 2011. Accessed March 2012. Available at URL address: http://www.ninds.nih.gov/disorders/autism/detail_autism.htm
110. National Institute of Neurological Disorders and Stroke (NINDS). National Institutes of Health. Pervasive Developmental Disorders Information Page. Last updated September 30, 2011. Accessed March 2012. Available at URL address: <http://www.ninds.nih.gov/disorders/pdd/pdd.htm>
111. National Research Council (NRC). 2001. Educating Children with Autism. Committee on Educational Interventions for Children with Autism. Catherine Lord and James P. McGee, eds. Division of Behavioral and Social Sciences and Education. Washington, DC: National Academy Press. Accessed March 2012. Available at URL address: <http://books.nap.edu/openbook.php?isbn=0309072697>
112. New York State Department of Health Early Intervention Program. Clinical Practice Guideline Report of the Guideline Recommendations Autism / Pervasive Developmental Disorders. Albany, NY: New York State Department of Health; 1999. Accessed March 2012. Available at URL address: [http://www.health.state.ny.us/community/infants_children/early_intervention/autism/index.htm#Table of Contents](http://www.health.state.ny.us/community/infants_children/early_intervention/autism/index.htm#Table_of_Contents)
113. Niederhofer H, Staffen W, Mair A. Immunoglobulins as an alternative strategy of psychopharmacological treatment of children with autistic disorder. Neuropsychopharmacology. 2003 May;28(5):1014-5. Epub 2003 Mar 26.
114. Nye C, Brice A. Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003497.
115. Odom SL, Boyd BA, Hall LJ, Hume K. Evaluation of comprehensive treatment models for individuals with autism spectrum disorders. J Autism Dev Disord. 2010 Apr;40(4):425-36.
116. Ospina MB, Krebs Seida J, Clark B, Karkhanavich M, Hartling L, Tjosvold L, et al. Behavioural and developmental interventions for autism spectrum disorder: a clinical systematic review. PLoS One. 2008;3(11):e3755.
117. Patel NC, Yeh JY, Shepherd MD, Crismon ML. Secretin treatment for autistic disorder: a critical analysis. Pharmacotherapy. 2002 Jul;22(7):905-14.
118. Pfeiffer BA, Koenig K, Kinnealey M, Sheppard M, Henderson L. Effectiveness of sensory integration interventions in children with autism spectrum disorders: a pilot study. Am J Occup Ther. 2011 Jan-Feb;65(1):76-85.
119. Prelock P. Understanding Autism Spectrum Disorders: The Role of Speech-Language Pathologists and Audiologists in Service Delivery. The ASHA leader online. American Speech-Language-Hearing Association (ASHA); September 25, 2001. Accessed March 2012. Available at URL address: http://www.asha.org/Publications/leader/2001/010925/understanding_ASQ.htm
120. Ratliff-Schaub K, Carey T, Reeves GD, Rogers MA. Randomized controlled trial of transdermal secretin on behavior of children with autism. Autism. 2005 Jul;9(3):256-65.
121. Reed P, Osborne LA, Corness M. Brief report: relative effectiveness of different home-based behavioral approaches to early teaching intervention. J Autism Dev Disord. 2007 Oct;37(9):1815-21.
122. Reichow B, Volkmar FR, Cicchetti DV. Development of the evaluative method for evaluating and determining evidence-



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

- based practices in autism. J Autism Dev Disord. 2008 Aug;38(7):1311-9. Epub 2007 Dec 18.
123. Reichow B, Wolery M. Comprehensive synthesis of early intensive behavioral interventions for young children with autism based on the UCLA young autism project model. J Autism Dev Disord. 2009 Jan;39(1):23-41.
 124. Reichow B. Overview of Meta-Analyses on Early Intensive Behavioral Intervention for Young Children with Autism Spectrum Disorders. J Autism Dev Disord. 2011 Mar 15.
 125. Remington B, Hastings RP, Kovshoff H, degli Espinosa F, Jahr E, Brown T, et al. Early intensive behavioral intervention: outcomes for children with autism and their parents after two years. Am J Ment Retard. 2007 Nov;112(6):418-38.
 126. Risch N, Spiker D, Lotspeich L, Nouri N, Hinds D, Hallmayer J, et al. A genomic screen of autism: evidence for a multilocus etiology. Am J Hum Genet. 1999 Aug;65(2):493-507.
 127. Rossignol DA, Rossignol LW, James SJ, Melnyk S, Mumper E. The effects of hyperbaric oxygen therapy on oxidative stress, inflammation, and symptoms in children with autism: an open-label pilot study. BMC Pediatr. 2007 Nov 16;7:36.
 128. Rossignol DA, Rossignol LW, Smith S, Schneider C, Logerquist S, Usman A, et al. Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial. BMC Pediatr. 2009;9: 21.
 129. Rossignol DA, Rossignol LW. Hyperbaric oxygen therapy may improve symptoms in autistic children. Med Hypotheses. 2006;67(2):216-28. Epub 2006 Mar 22.
 130. Sadock BJ, Sadock VA, Ruiz P, editors. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, 9th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2009.
 131. Sallows GO, Graupner TD. Intensive behavioral treatment for children with autism: four-year outcome and predictors. Am J Ment Retard. 2005 Nov;110(6):417-38.
 132. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999 Dec 9;341(24):1801-6.
 133. Santangelo SL, Tsatsanis K. What is known about autism: genes, brain, and behavior. Am J Pharmacogenomics. 2005;5(2):71-92.
 134. Saul RA, Tarleton JC. FMR1 Related Disorders. Gene Reviews. Funded by the NIH. Developed at the University of Washington, Seattle. Initial posting: June 16 1998. Last Update: June 16, 2011. Accessed March 2012. Available at URL address: <http://www.ncbi.nlm.nih.gov/books/NBK1384/>
 135. Schaefer GB, Lutz RE. Diagnostic yield in the clinical genetic evaluation of autism spectrum disorders. Genet Med. 2006 Sep;8(9):549-56.
 136. Schaefer GB, Mendelsohn NJ. Genetics evaluation for the etiologic diagnosis of autism spectrum disorders. Genet Med. 2008 Jan;10(1):4-12.
 137. Schaefer GB, Mendelsohn NJ; Professional Practice and Guidelines Committee. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders. Genet Med. 2008 Apr;10(4):301-5.
 138. Schlosser RW, Wendt O. Effects of augmentative and alternative communication intervention on speech production in children with autism: a systematic review. Am J Speech Lang Pathol. 2008 Aug;17(3):212-30.
 139. Scottish Intercollegiate Guidelines Network (SIGN). Assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2007 Jul. Accessed March 2012. Available at URL address: <http://www.sign.ac.uk/pdf/sign98.pdf>
 140. Seida JK, Ospina MB, Karkhaneh M, Hartling L, Smith V, Clark B. Systematic reviews of psychosocial interventions for autism: an umbrella review. Dev Med Child Neurol. 2009 Feb;51(2):95-104.
 141. Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004 Nov;114(5):e634-41. Epub 2004 Oct 18.
 142. Shea V. A perspective on the research literature related to early intensive behavioral intervention (Lovaas) for young children with autism. Autism. 2004 Dec;8(4):349-67.
 143. Sheinkopf S, Siegel B. Home-based behavioral treatment of young children with autism. J Autism Devel Disord. 1998

MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

Feb;28(1):15-23.

144. Shen Y, Dies KA, Holm IA, Bridgemohan C, Sobeih MM, Caronna EB, et al; Autism Consortium Clinical Genetics/DNA Diagnostics Collaboration. Clinical genetic testing for patients with autism spectrum disorders. *Pediatrics*. 2010 Apr;125(4):e727-35. Epub 2010 Mar 15.
145. Sherman S, Pletcher BA, Driscoll DA. Fragile X syndrome: diagnostic and carrier testing. *Genet Med*. 2005 Oct;7(8):584-7.
146. Sinha Y, Silove N, Wheeler D, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders. *Cochrane Database Syst Rev*. 2004;(1):CD003681.
147. Sinha Y, Silove N, Wheeler D, Williams K. Auditory integration training and other sound therapies for autism spectrum disorders: a systematic review. *Arch Dis Child*. 2006 Dec;91(12):1018-22. Epub 2006 Aug 3.
148. Smith SA, Press B, Koenig KP, Kinnealey M. Effects of sensory integration intervention on self-stimulating and self-injurious behaviors. *Am J Occup Ther*. 2005 Jul-Aug;59(4):418-25.
149. Smith T, Groen A, Wynn J. Randomized trial of intensive early intervention for children with pervasive developmental disorder. *Am J Ment Retard*. 2000 Jul;105(4):269-85. Erratum in: *Am J Ment Retard* 2000 Nov;105(6):508. *Am J Ment Retard* 2001 May;106(3):208.
150. Spreckley M, Boyd R. Efficacy of Applied Behavioral Intervention in Preschool Children with Autism for Improving Cognitive, Language, and Adaptive Behavior: A Systematic Review and Meta-analysis. *J Pediatr*. 2008 Oct 22.
151. The Autism Genome Project Consortium; Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, Liu XQ, Vincent JB, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. *Nat Genet*. 2007 Mar;39(3):319-28. Epub 2007 Feb 18.
152. Thompson L, Thompson M, Reid A. Functional neuroanatomy and the rationale for using EEG biofeedback for clients with Asperger's syndrome. *Appl Psychophysiol Biofeedback*. 2010 Mar;35(1):39-61.
153. Thompson L, Thompson M, Reid A. Neurofeedback outcomes in clients with Asperger's syndrome. *Appl Psychophysiol Biofeedback*. 2010 Mar;35(1):63-81.
154. Toda Y, Mori K, Hashimoto T, Miyazaki M, Nozaki S, Watanabe Y, et al. Administration of secretin for autism alters dopamine metabolism in the central nervous system. *Brain Dev*. 2006 Mar;28(2):99-103.
155. Tuchman R. Autism. *Neurol Clin*. 2003 Nov;21(4):915-32, viii.
156. U.S. Food and Drug Administration (FDA). FDA News. FDA Approves the First Drug to Treat Irritability Associated with Autism, Risperdal. October 2006. Accessed March 2012. Available at URL address: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108759.htm>
157. van der Meer LA, Rispoli M. Communication interventions involving speech-generating devices for children with autism: a review of the literature. *Dev Neurorehabil*. 2010;13(4):294-306.
158. Van Naarden Braun K, Pettygrove S, Daniels J, Miller L, Nicholas J, Baio J, et al.; Centers for Disease Control and Prevention. Evaluation of a methodology for a collaborative multiple source surveillance network for autism spectrum disorders--Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2002. *MMWR Surveill Summ*. 2007 Feb 9;56(1):29-40.
159. Virués-Ortega J. Applied behavior analytic intervention for autism in early childhood: meta-analysis, meta-regression and dose-response meta-analysis of multiple outcomes. *Clin Psychol Rev*. 2010 Jun;30(4):387-99. Epub 2010 Feb 11.
160. Volkmar F, Cook E Jr, Pomeroy J, Realmuto G, Tanguay P. Summary of the Practice Parameters for the Assessment and Treatment of Children, Adolescents, and Adults with Autism and other Pervasive Developmental Disorders. American Academy of Child and Adolescent Psychiatry. *J Am Acad Child Adolesc Psychiatry*. 1999 Dec;38(12):1611-6.
161. Volkmar F, Cook EH Jr, Pomeroy J, Realmuto G, Tanguay P. Practice parameters for the assessment and treatment of children, adolescents, and adults with autism and other pervasive developmental disorders. American Academy of Child and Adolescent Psychiatry Working Group on Quality Issues. *J Am Acad Child Adolesc Psychiatry*. 1999 Dec;38(12 Suppl):32S-54S.
162. Volkmar FR, Lord C, Bailey A, Schultz RT, Klin A. Autism and pervasive developmental disorders. *J Child Psychol Psychiatry*. 2004 Jan;45(1):135-70.



MEDICAL COVERAGE POLICY

SERVICE: Autism Spectrum Disorder

Policy Number: 206

Effective Date: 08/01/2024

Last Review: 07/24/2024

Next Review: 07/24/2025

163. Vorgrat Y, Farbstein I, Spiegel R, Apter A. Retrospective evaluation of an intensive method of treatment for children with pervasive developmental disorder. *Autism*. 2007 Sep;11(5):413-24.
164. Warren Z, McPheeters ML, Sathe N, Foss-Feig JH, Glasser A, Veenstra-Vanderweele J. A systematic review of early intensive intervention for autism spectrum disorders. *Pediatrics*. 2011 May;127(5):e1303-11. Epub 2011 Apr 4.
165. Warren Z, Veenstra-Vanderweele J, Stone W, Bruzek JL, Nahmias AS, Foss-Feig JH, et al. Therapies for Children With Autism Spectrum Disorders. Comparative Effectiveness Review No. 26. (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I.) AHRQ Publication No. 11-EHC029-EF. Rockville, MD: Agency for Healthcare Research and Quality. April 2011. Accessed March 2012. Available at URL address: <http://www.effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=656>
166. Weber W, Newmark S. Complementary and alternative medical therapies for attention-deficit/hyperactivity disorder and autism. *Pediatr Clin North Am*. 2007 Dec;54(6):983-1006.
167. Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, et al.; Autism Consortium. Association between microdeletion and microduplication at 16p11.2 and autism. *N Engl J Med*. 2008 Feb 14;358(7):66775. Epub 2008 Jan 9.
168. White AH. Cognitive behavioural therapy in children with autistic spectrum disorders. In Bazian Ltd (Ed) *STEER: Succinct and Timely Evaluated Evidence Reviews* 2004; 4(5). Bazian Ltd and Wessex Institute for Health Research & Development, University of Southampton. Accessed March 2012. Available at URL address: [http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2004\(5\).pdf](http://www.wihrd.soton.ac.uk/projx/signpost/steers/STEER_2004(5).pdf)
169. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. *Cochrane Database Syst Rev*. 2005 Jul 20;(3):CD003495.
170. Wong VC, Chen WX. Randomized controlled trial of electro-acupuncture for autism spectrum disorder. *Altern Med Rev*. 2010 Jul;15(2):136-46.
171. Zachor D.A., Ben Itzhak E. Treatment approach, autism severity and intervention outcomes in young children. *Research in Autism Spectrum Disorders*, 2010 4(3), pp. 425-432.

Note:

Health Maintenance Organization (HMO) products are offered through Scott and White Health Plan dba Baylor Scott & White Health Plan, and Scott & White Care Plans dba Baylor Scott & White Care Plan. Insured PPO and EPO products are offered through Baylor Scott & White Insurance Company. Scott and White Health Plan dba Baylor Scott & White Health Plan serves as a third-party administrator for self-funded employer-sponsored plans. Baylor Scott & White Care Plan and Baylor Scott & White Insurance Company are wholly owned subsidiaries of Scott and White Health Plan. These companies are referred to collectively in this document as Baylor Scott & White Health Plan.

RightCare STAR Medicaid plans are offered through Scott and White Health Plan in the Central Managed Care Service Area (MRSA) and STAR and CHIP plans are offered through SHA LLC dba FirstCare Health Plans (FirstCare) in the Lubbock and West MRSA.